Peptide Half-Life in Research: Proteolysis, Clearance and Extension Chemistry
Why native peptides last minutes, how Aib, lipidation, albumin binding, PEG and Fc fusion extend half-life, and how serum and plasma stability assays work.
By the APL Research Team · Updated · First published · 7 min read
"Half-life" means different things depending on where a peptide is: in a vial, in a tube of plasma, or in an organism. Native signalling peptides are cleared in minutes by proteolysis and renal filtration [1], and much of modern peptide chemistry exists to slow that down. This guide covers why peptides disappear, the main extension strategies with worked examples, and how to measure stability in vitro so that an experiment tests pharmacology rather than degradation.
What half-life means for a peptide
For a process that follows first-order kinetics, the half-life is the time for the concentration to fall by half: t½ = ln 2 / k, where k is the rate constant. After five half-lives about 3% remains. The definition is the same in every context, but what drives k is not.
| Context | What is measured | What sets the rate | Where it matters |
|---|---|---|---|
| Storage stability | Loss of intact peptide in the vial or stock solution | Water, temperature, pH, oxygen | Shelf life, stock handling |
| Matrix stability | Loss in serum, plasma, blood or culture medium at 37 °C | Proteases in the matrix | In-vitro assay design |
| Elimination half-life | Fall in plasma concentration in an organism | Proteolysis, renal and hepatic clearance, protein binding | Pharmacokinetics |
The gap between matrix and elimination half-life can be large. Human plasma in vitro degraded GLP-1(7–36)amide with a half-life of about 20 minutes at 37 °C [2], yet the native hormone's half-life in circulation is described in minutes [3], because clearance adds to proteolysis.
Why native peptides disappear quickly
Short plasma half-lives are mainly due to fast renal clearance and enzymatic degradation in the circulation [1]. Natural peptides typically show rapid clearance, short half-lives and low membrane permeability [4].
Proteolysis
Proteases cut at specific sequence motifs, so a single vulnerable bond can decide a peptide's fate. Dipeptidyl peptidase-IV (DPP-IV), which removes N-terminal dipeptides, is the clearest example in research peptides.
| Peptide | Cleavage | Enzyme | Evidence |
|---|---|---|---|
| GLP-1(7–36)amide | Removes residues 7–8, giving inactive GLP-1(9–36)amide | DPP-IV; blocked by DPP-IV inhibitors or 4 °C, not by EDTA or aprotinin | Human plasma in vitro [2] |
| GHRH(1–44)NH₂ and GHRH(1–29)NH₂ | Removes residues 1–2; also cut at 11–12 | DPP-IV, then trypsin-like enzymes | Human plasma in vitro [5] |
The in-vitro result held in vivo. After intravenous GLP-1, intact peptide accounted for only about 20% of the rise in C-terminal immunoreactivity in healthy subjects; the remainder was the truncated metabolite [6]. Unmodified research peptides show the same pattern: intact BPC-157 had an elimination half-life under 30 minutes in rats and beagle dogs, and labelled peptide was broken down rapidly into small fragments and then amino acids [7].
Renal clearance
Many therapeutic molecules are smaller than the renal filtration threshold and are lost rapidly from the circulation, whereas albumin persists because of its size and its interaction with the FcRn recycling pathway [8]. Most extension strategies exploit one or both mechanisms: they make the peptide effectively larger, or tie it to a protein that is protected from clearance.
Half-life extension strategies
| Strategy | Mechanism | Example | Reported effect |
|---|---|---|---|
| D-amino acids, shortened sequence | Protease resistance | Octreotide vs somatostatin | 1.5 h vs a few minutes [1] |
| Aib substitution | Blocks DPP-IV at position 2 of the active peptide | Semaglutide (Aib8) | Part of a combined design, below [9] |
| N-terminal acylation | Blocks DPP-IV | Tesamorelin (trans-3-hexenoyl on Tyr1) | DPP-IV resistant; slower degradation in plasma [10] |
| Fatty-acid acylation | Reversible albumin binding | Liraglutide, semaglutide | Mini-pig plasma t½ 46.1 h for semaglutide [9] |
| Covalent albumin conjugation | Peptide bonds to albumin Cys34 | CJC-1295 (DAC) | Human t½ 5.8–8.1 days [11] |
| PEGylation | Larger hydrodynamic size; shields from proteases | PEG-interferon α-2b | 330-fold longer than native protein [1] |
| Fc fusion | Larger size; FcRn recycling | Dulaglutide (LY2189265) | t½ 1.5–2 days in rats and monkeys [3] |
Residue substitution: D-amino acids and Aib
Replacing a cleavage-site residue removes the motif a protease recognises. D-amino acid substitution at position 1 or 2 of GHRH prevented DPP-IV hydrolysis [5], and the octreotide example above combines D-residues with a shortened sequence [1]. Semaglutide replaces alanine at position 8 with Aib, α-aminoisobutyric acid, as one of two substitutions relative to human GLP-1 [9]; position 8 is the second residue of the active peptide, exactly where DPP-IV cuts [2].
Acylation and albumin binding
Attaching a fatty acid lets a peptide bind albumin reversibly, and the fatty acid and linker were the variables optimised to maximise albumin affinity while keeping GLP-1 receptor potency in the liraglutide and semaglutide programmes [12]. In semaglutide, Lys26 carries an 18-carbon fatty diacid joined through a γ-glutamate and two short ethylene-glycol-based spacers [9]. Compared with liraglutide its receptor affinity was three-fold lower (0.38 nM) but its albumin affinity higher, and its plasma half-life in mini-pigs was 46.1 hours after intravenous administration [9]. The trade of some intrinsic potency for much longer exposure is typical of the approach, and lipidation is reviewed more broadly elsewhere [13].
Covalent albumin conjugation: CJC-1295 with DAC
The drug affinity complex (DAC) approach places a reactive maleimide on the peptide so that it bonds to the free thiol of albumin's Cys34. CJC-1295 is a tetrasubstituted GHRH(1–29) analogue with a maleimidopropionyl-modified lysine added at the C-terminus; the albumin conjugates resisted DPP-IV in vitro, and the peptide was still detectable in rat plasma beyond 72 hours [14]. In healthy adults its estimated half-life was 5.8–8.1 days [11].
PEGylation and Fc fusion
PEGylation attaches polyethylene glycol chains, increasing molecular mass and shielding the peptide from proteolytic enzymes [15]. Larger PEGs give longer half-lives; as PEG size increases, renal elimination of the polymer falls and biliary excretion rises [16]. Fc fusion achieves a similar result genetically: an IgG4 Fc fusion of a GLP-1 analogue retained full receptor activity in vitro and had a half-life of 1.5–2 days in rats and cynomolgus monkeys [3].
Two families compared
The GHRH analogues show how different modifications on the same scaffold change behaviour.
| Peptide | Modification | Stability or half-life data |
|---|---|---|
| Native GHRH(1–44)NH₂ | None | Cleaved by DPP-IV at 2–3 and trypsin-like enzymes in plasma [5] |
| Tesamorelin | trans-3-Hexenoyl on Tyr1 of GHRH(1–44)NH₂ | DPP-IV resistant; apparent elimination t½ 21–45 min in dogs [10] |
| CJC-1295 (no DAC) | Four substitutions in GHRH(1–29)NH₂, including D-Ala2 | No peer-reviewed pharmacokinetic study located |
| CJC-1295 (DAC) | As above, plus C-terminal Lys with maleimide for albumin conjugation | >72 h in rat plasma; human t½ 5.8–8.1 days [11, 14] |
For GLP-1, the native hormone lasts minutes [3]; semaglutide, with Aib8 and a lipidated Lys26, had a 46.1-hour half-life in mini-pigs [9]; and the Fc fusion LY2189265 lasted 1.5–2 days in rats and monkeys [3]. Species matters in every one of these numbers, which is why mini-pig, dog, rat and human values should never be compared as if interchangeable.
Measuring stability in vitro
A matrix stability assay incubates the peptide in serum, plasma, blood or culture medium at 37 °C, stops the reaction at set times and measures what is left. Each of those steps has been shown to change the answer.
Matrix. Peptides from three families were generally degraded faster in serum than in plasma, were more stable in fresh mouse blood than in either, and ranked differently across six incubation conditions [17]. Coagulation activates proteases in serum; EDTA in plasma inhibits metallo- and calcium-dependent proteases and heparin inhibits enzymes such as thrombin and factor Xa [17]. The authors concluded that efforts to stabilise peptides against serum or plasma proteases may target sites of limited relevance in vivo [17].
Stopping the reaction. For GLP-1, a DPP-IV inhibitor or cooling to 4 °C stopped degradation, whereas EDTA and aprotinin did not [2]. A quench that does not inhibit the relevant enzyme lets degradation continue in the sample queue.
Sample preparation. Precipitating plasma proteins with strong acids lost peptide, whereas mixtures of organic solvents preserved more for analysis; fluorescent labels also affected stability compared with isotopic labels [18].
Readout. Antisera directed at a peptide's C-terminus or mid-region recognise both intact GLP-1 and its inactive N-terminally truncated metabolite, which is why HPLC separation was needed to measure the intact form [2]. LC-MS that resolves the parent from its fragments avoids the problem.
Worked example
| Time (min) | Intact peptide remaining |
|---|---|
| 0 | 100% |
| 15 | 80% |
| 30 | 63% |
| 60 | 40% |
| 120 | 16% |
Plotting ln(% remaining) against time gives a straight line for first-order loss. From the 60-minute point, k = −ln(0.40) / 60 = 0.0153 min⁻¹, so t½ = 0.693 / 0.0153 ≈ 45 minutes; the 120-minute value (16%, about two and a half half-lives) is consistent. Fitting all points by regression is better than using one, and a curved plot suggests more than one process, such as rapid initial adsorption followed by proteolysis.
What it means for in-vitro experiments
- Exposure is not the nominal concentration. If half the peptide is gone in 45 minutes, a 24-hour incubation exposes cells mostly to fragments. Measure intact peptide at the start and end, or replenish the medium.
- Match exposure when comparing analogues. Comparing a native sequence with a stabilised analogue at a single late time point mostly measures their difference in stability.
- Consider binding partners. Albumin-binding analogues behave differently with and without albumin or serum in the medium, because the bound fraction is not free to act at the receptor.
- Plan time points from stability data. The dose–response design guide covers how incubation time interacts with potency estimates, and sterile technique keeps microbial proteases out of stocks.
For the bench
- Read the sequence first: free N-termini with Ala or Pro at position 2, unprotected Lys/Arg sites and the absence of D-residues or Aib all predict faster proteolysis. How to read peptide sequences explains the notation.
- Keep stocks out of serum until the assay starts, and store them as frozen single-use aliquots.
- Confirm the parent mass by mass spectrometry at time zero so that fragments seen later can be assigned.
- Use the molarity calculator to express concentrations in molar units; half-life comparisons between peptides of different size are only meaningful in moles.
- Lipidated incretin analogues are listed in the metabolic research range and GHRH analogues in the GH secretagogue range; what are research peptides sets out how these reagents differ from the approved medicines that share some of their chemistry.
Frequently asked questions
Is a peptide's half-life the same as its shelf life?
No. Shelf life describes chemical stability of the stored reagent, usually as a lyophilised solid; half-life in the pharmacological sense describes how quickly the peptide disappears from blood, plasma or an organism. A peptide can keep for years as a dry powder at −20 °C and still be cut in minutes by plasma enzymes, as native GLP-1 is [2]. The storage guide covers the first kind; this guide the second.
What is the half-life of semaglutide?
In the discovery paper, semaglutide's plasma half-life was 46.1 hours in mini-pigs after intravenous administration, with a mean residence time of 63.6 hours after subcutaneous administration in the same species [9]. The extension comes from an Aib substitution at position 8 that resists DPP-IV and a fatty-acid side chain on Lys26 that binds albumin reversibly [9, 12]. The semaglutide page lists the reagent's specifications.
Why does CJC-1295 with DAC last so much longer than CJC-1295 without it?
The DAC version carries a reactive maleimide group on an added C-terminal lysine that bonds covalently to cysteine 34 of serum albumin, so the peptide circulates with albumin; in rats it was still present in plasma beyond 72 hours [14], and in healthy adults its estimated half-life was 5.8–8.1 days [11]. The version without DAC lacks that group. We did not locate a peer-reviewed pharmacokinetic study of it; see the CJC-1295 (no DAC) page for the reagent itself.
Should a stability assay use serum or plasma?
It depends on the question, and the answer can change the result. In a mouse study, peptides from three families were generally degraded faster in serum than in plasma, were more stable in fresh whole blood than in either, and even ranked differently from one matrix to another [17]. Coagulation activates proteases in serum, while anticoagulants such as EDTA or heparin inhibit some enzymes in plasma [17]. Report the matrix, species and anticoagulant.
Does a long in-vivo half-life mean a peptide is stable in cell culture medium?
Not necessarily. Albumin-binding analogues owe much of their protraction to reversible binding to albumin [12] and to albumin's own recycling [8], neither of which operates the same way in a serum-free well. Protease content also differs between media: degradation in two cell-culture supernatants varied widely between model peptides [18]. Measure stability in the actual assay medium.
How does an Aib residue protect a peptide?
Aib (α-aminoisobutyric acid) carries two methyl groups on its alpha carbon, which hinders the protease that would otherwise cut next to it. In semaglutide it replaces alanine at position 8 to block DPP-IV [9], the enzyme that removes the first two residues of native GLP-1 in plasma [2]. The same enzyme attacks GHRH, where a D-amino acid at position 1 or 2 also prevented cleavage [5]. How to read peptide sequences explains the notation.
References
- 1.Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006. PubMed 16622600
- 2.Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995. PubMed 7883856
- 3.Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010. PubMed 20503261
- 4.Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015. PubMed 25366889
- 5.Frohman LA, Downs TR, Heimer EP, et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989. PubMed 2565342
- 6.Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995. PubMed 7657039
- 7.He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PubMed 36588717
- 8.Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013. PubMed 23639804
- 9.Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015. PubMed 26308095
- 10.Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007. PubMed 17214611
- 11.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- 12.Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019. PubMed 31031702
- 13.Menacho-Melgar R, Decker JS, Hennigan JN, et al. A review of lipidation in the development of advanced protein and peptide therapeutics. J Control Release. 2019. PubMed 30579981
- 14.Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PubMed 15817669
- 15.Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003. PubMed 12612647
- 16.Fornasari DMM. PEGylated Proteins: How Much Does Molecular Weight Matter?. Clin Pharmacokinet. 2025. PubMed 41006726
- 17.Böttger R, Hoffmann R, Knappe D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One. 2017. PubMed 28575099
- 18.Kohler A, Jülke EM, Stichel J, et al. Comparison of Protocols to Test Peptide Stability in Blood Plasma and Cell Culture Supernatants. ACS Pharmacol Transl Sci. 2024. PubMed 39539263
This article summarises published research for educational purposes. It is not medical advice. Compounds sold by Australian Peptide Lab are research reagents for in-vitro laboratory use only, not for human or veterinary use.
